Nonetheless, there are strict requirements for targeted therapy in GC, such as human epidermal growth factor receptor-2 (HER-2) positivity, vascular endothelial growth factor receptor (VEGFR) positivity, and programmed cell death-ligand 1 (PD-L1) overexpression (10). This evidence concerns the gene ERBB2 and gastric cancer.